致死性败血症,物氟伏沙明 z-bo 2020-09-29 346

　　Septis is the leading cause of death in the world's population, and the Federal Centers for Disease Control and Prevention calls it "the extreme human response to infection." Essentially, when the body's immune response is out of control, it is usually beneficial inflammation. This reaction can be harmful and can cause tissue damage, organ failure and even death. In the latest research report published in the international journal "Science Translational Medicine", scientists at the University of Virginia have identified drugs that are expected to prevent deadly sepsis through their research. Researcher Alban Gaultier said sepsis is very dangerous.

　　In the United States, 1.7 million people suffer from sepsis every year, and 270,000 people die from the disease. When diagnosed with sepsis, the risk of death is very high. Currently, there is no best cure for sepsis. Basically, clinicians will try to keep sepsis patients alive and monitor as much as possible, but it is clear that patients need urgent treatment. In this study, the researchers identified a new type of drug that is expected to treat sepsis. In the past, researchers' safety trials of the drug may accelerate its use in hospitals across the country; researchers use one of the cells to study less studied biological processes. Play an important role in regulating inflammation in the body. The reason why researchers study this biological process is that certain drugs play an important role in this process. Gautier said that inflammation is beneficial in most cases, but if it gets out of control, it must be adjusted in time. If inflammation is needed and there is too much inflammation, inflammation is a very accurate control response. There are problems, but if the degree of inflammation is insufficient, there will be other problems. In order to evaluate the potential of this antidepressant called fluoroboxamine to block sepsis, the researchers tested it in a murine sepsis model, and the results showed that fluboxamine can effectively block sepsis in mice. Occurrence and progress. Currently, researchers need to test in humans to determine the drug's therapeutic effect on human sepsis. Previous tests to determine the safety of the drug may speed up this process.

　　Researcher Gaultier hypothesized that when the body needs it, it may produce a beneficial inflammatory response to the same biological process. For example, for people with weakened immunity, blocking specific receptors allows researchers to rejuvenate their bodies without proper inflammation. This response reflects the inflammatory response in the patient. In the next step, researchers will continue to conduct in-depth research to detect the effects of floxamine, hoping to develop more new therapies for the treatment of sepsis in the future.